Chapter 25

# Innovation and Intersection in Human and Veterinary Vaccine Development

Farhad Badshah[1,2,3], Muhammad Tariq[4,5], Azka Manzoor[6], Muhammad Salman Khan[1*], Ikram Ullah[7], Sohail Anjum[8], Zia Ul Islam[9], Mubashir Ullah[1], Saboor Badshah[10] and Farooq Ahmad[1]

[1]Department of Zoology, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
[2]State Key Laboratory of Animal Biotech Breeding, Institute of Animal Science, Chinese Academy of Agricultural Science, Beijing 100193, China
[3]Shenzhen Branch, Guangdong Laboratory of Lingnan Modern Agriculture, Key Laboratory of Livestock and Poultry Multi-Omics of MARA, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518000, China
[4]Department of Zoology, Cholistan University of Veterinary Science Bahawalpur
[5]Collage of Animal Science and Technology, Nanjing Agricultural University, Nanjing, Jiangsu, 210095, PR China
[6] The Islamia University of Bahawalpur, South Punjab, 63100, Pakistan
[7]School of Biological Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia
[8]Department of Zoology University of Malakand, Chakdara 18800, Dir Lower
[9]Department of Zoology, Shaheed Benazir Bhutto University Sheringal, Upper Dir 18050, Pakstan
[10]Department of Botany, Kohat University of Science and Technology, Kohat, 2600, Pakistan
*Corresponding author: Muhammad Salman Khan; salman.khan@awkum.edu.pk

**ABSTRACT**

This chapter mainly focuses on the significance of immunization not only in the public health but also in animal health. Also, it reveals striking similarities in human and animal vaccine development. It starts with emphasizing the historical contribution of vaccines to the control of diseases to help dwell on the recent scientific progress in the said field. These include the advent of platforms based on mRNA vaccines and a shift in perspectives from traditional to modern ones being data-driven through science and nanotechnology, which in turn shape how vaccines are designed and distributed. An integral part of the present essay consists of analyzing the intricate symbiotic linkage that is observed between human and veterinary vaccine research where the "One Health" concept depicts itself as an instruction. It is the way to underline and consider the interconnectivity of human, animal, and environmental health and how the improvements in one can be quite positive in ones-side. Although, by now the chapter covers some important achievements, at the same time he puts the challenges that still exist in the line of fire, like the rise of an original pathogen spreading, vaccine resistance, and the gap of access in a global circle. It ends with a prospective direction sheerly emphasizing the fact that the progress should not stop and all fields of science should be running it together seeking solutions for the next challenges in vaccine research and development. This chapter has a lot of relevant information about vaccination in the dynamically changing world that represents a momentary sensation of how interdependent vaccine development is for global health.

| KEYWORDS | | |
|---|---|---|
| Animal health, immunization, mRNA vaccine, One Health, vaccine development | Received: 18-Jun-2024<br>Revised: 19-Jul-2024<br>Accepted: 20-Aug-2024 | A Publication of Unique Scientific Publishers |

**Cite this Article as:** Badshah F, Tariq M, Manzoor A, Khan MS, Ullah I, Anjum S, Islam Z, Ullah M, Badshah S, Ahmad F, 2024. Innovation and intersection in human and veterinary vaccine development. In: Asad M, Hussain R, Toor SI, Mughal MAS and Ahmad M (eds), Complementary and Alternative Medicine: Non-Conventional Therapies. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 206-216. https://doi.org/10.47278/book.CAM/2024.476

## INTRODUCTION

Immunization is essential for the maintenance of good health in both people and animals. Immunology in zoology is fascinating because differences and similarities in immune systems among animals from various orders and species continue to be observed. The immune system of an animal is very complex and individual immune systems of animals very distinct, but the basic principles of pathogen identification and memory upon subsequent exposure to that pathogen are the same for all species (Janeway et al., 2001). The adaptive immune system of humans includes antibodies, B cells, and T cells. From this example, humans and animals use the same elements to defend against infection; however, animals adapt the elements based on what they have encountered in the past with different organisms. In veterinary vaccines, the antigenic determinants, which are focused on intracellular infections for the purposes (Murphy et al., 2012).

This medical breakthrough was the first step for humans to further develop vaccinations to eradicate smallpox (Fenner et al., 1988). A fascinating history of human medicine began in the nineteen centuries with Louis Pasteur, who produced the first vaccine to immunize cattle and saved France's cattle industry from collapse from anthrax (Brock, 1999). The paper introduces the notion of health interconnectedness between humans and animals as discussed by (Geison *et al*., 1978). According to the World Health Organization (WHO) in 2020 the One Health concept (OHC) was established because of the inter connectedness of humans, animals, and the environment. It recognizes that the health of people is connected to the health of animals and the environment. Understanding the importance of vaccination for both humans and animals is crucial. The ongoing research on vaccinations continues to shed light on the role of immunology in disease prevention. This allows us to be ready for emerging diseases that can affect both animals and humans.

**Comparative Immunology: Similarities and Differences between Human and Animal Immune Systems**

Comparative immunology approaches the understanding of the changes governed by genetics, which are closely linked to the different nature and severity of diseases. Humans have a highly sophisticated immune system that is often classified into two parts: The Innate immunity and Adaptive immune systems. The adaptive system, ironically, is the by-product of vaccination. It shows itself to be a strong innate response system (Janeway et al., 2001). Much as there is an overwhelming difference, an immune system (found majorly in mammals and animals) is simply present. The bursa of Fabricius, which helps B lymphocytes to develop is a specific organ in birds only. Human bodies, meanwhile, have bone marrow, not Fabricius's bursa for this process (Ratcliffe, 2006). Conversely, fish are less adaptive and depend more on their bodies' defences (Uribe et al., 2011).

Despite their diversity, one facet of immunity is shared by all vertebrates when it comes to the interplay between health and illness. Vaccines that are effective in various immune systems may be designed with these similarities and variances in mind (Zhang et al., 2014). Insight into these parallels strengthens our strategy for illness prevention, paving the way for the creation and administration of vaccines that consider the differences between the immune responses of animals and humans.

**Historical Milestones in Human and Veterinary Vaccines**

The development of vaccinations and their subsequent influence on animal and public health are remarkable examples of human ingenuity. An early kind of smallpox vaccination in Asia before the 17th century, smallpox injection may have been how immunization took place (Behbehani, 1983). Modern vaccines began with Edward Jenner's smallpox vaccine in 1796 (Fig. 1), which introduced the use of the cowpox virus to provide human immunity against smallpox (Riedel, 2005). This not only eliminated smallpox but also laid the foundation for the idea of vaccination. A breakthrough in veterinary research was Louis Pasteur's development of the anthrax vaccine in 1881. His subsequent invention of the rabies vaccine in 1885 marked a significant moment in the treatment of humans and animals (Pasteur, 1885). These findings confirm that control of animal diseases, especially zoonotic diseases, can benefit human health.




**Fig. 1:** History of major human vaccine development (Kumari et al., 2022).

Other important developments include the introduction of inactivated vaccines, such as the polio vaccine developed by Jonas Salk in 1955, and later live vaccines, such as Albert Sabin's oral polio vaccine (Offit, 2005). The 20th century saw the development of safe and effective vaccines against various infectious diseases in humans and animals become widespread. The advent of genetic engineering and recombinant DNA technology in the 21st century has revolutionized vaccine development and led to the rapid development of complex vaccines, such as human papillomavirus (HPV) blocking vaccines and the mRNA COVID-19 vaccine (Zimmer et al., 2020). Cooperation between people and veterinarians, promoting the One Health Strategy and joint efforts against infectious diseases.

**Types of Vaccines in Human and Veterinary Medicine**

Vaccines are biological preparations that provide active acquired immunity to a particular infectious disease. They contain agents resembling a disease-causing microorganism and are often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins.

Live-Attenuated Vaccines: These vaccines use a weakened form of the germ that causes a disease. They prompt a robust immune response and often confer lifelong immunity with just one or two doses. In human medicine, examples include the MMR (measles, mumps, and rubella) vaccine (Plotkin et al., 2012). Similarly, in veterinary medicine, live-attenuated vaccines are used, such as the canine parvovirus vaccine (Roura et al., 2021).

Inactivated Vaccines: Inactivated vaccines use the killed version of the germ that causes a disease. They are safer than live vaccines and are used when a live vaccine is deemed too risky. Human examples include the polio vaccine (IPV) (Orenstein et al., 2017), and veterinary examples include the rabies vaccine for pets (Brunette Gary and Nemhauser Jeffrey, 2020).

Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines: These vaccines use pieces of the germ — like its protein, sugar, or capsid (a casing around the germ). In humans, the HPV vaccine is a notable example (Schiller and Lowy, 1996). For animals, the leptospirosis vaccine is one such vaccine that protects against the bacteria without using a whole-cell preparation (Ellis, 2015).

Toxoid Vaccines: Toxoid vaccines are used against bacteria that produce toxins in the body. They are inactivated toxins (toxoids). The diphtheria and tetanus vaccines are examples in human medicine (Plotkin et al., 2012). For animals, a toxoid vaccine is used for tetanus in horses (Mealey, 2014).

DNA Vaccines: These are the latest type of vaccines that are currently being researched and have been used in veterinary medicine for diseases such as West Nile virus in horses (Kutzler and Weiner, 2008). They involve the direct injection of genetic material into the host, which cells then use to produce an antigen.

mRNA Vaccines: The mRNA vaccines, which include some COVID-19 vaccines, are a new type of vaccine to protect against infectious diseases. They teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies (Pardi et al., 2018).

**Species-Specific Vaccine Development and Use Cases**

Strain-specific vaccines play an important role in the prevention of various diseases affecting livestock that pose a threat to human health. For example, vaccines like the feline leukaemia virus vaccine for cats and the equine influenza virus vaccine for horses target specific diseases that are common in these animals (Dodds, 2021). In addition, vaccines like the rabies vaccine work though prevent zoonotic diseases, of animal origin. They can be transmitted to humans, and not only to domestic animals but also to wildlife and livestock (Abidin and Budi, 2021).

**Vaccine Development and Regulatory Considerations**

The iteration of these drugs needs to follow meticulous knowledge acquisition on the specific immune responses of that species, including the nature of the co-infection, the interactions between the hosts, pathogens, and environment between which (Wakhusama et al., 2019). For the sake of safe and precise performance of such a complex task as it is, such actors as research, public health authorities, and veterinarians need to engage in collaboration.

In a case of regurgitation, the process of regulating vaccine creations which is under few regulatory organizations such as FDA or EMA seems to be very complicated. Drug companies test clinical trials by vaccination to verify for safety and effectiveness before vaccines are authorized for manufacturing and distribution. We should also keep in mind a good strategy through the process of post-marketing surveillance inspections (Cole et al., 2022). We are coming to a new realization that fighting the spread of viral infections needs to abandon the unified plot that considers the health of humans, animals, and the environment (Erkyihun and Alemayehu, 2022). The working together of disciplines is of great historical importance in the reduction of disease and the recognition of coexistence and transfer of different vectors. Human and animal immunization regimens are customized to address unique requirements and dangers. Human vaccination schedules, recommended by health authorities such as the CDC or WHO, are based on factors such as age, risk of infection, and immune competence (CDC, 2020) and animal vaccination schedules also varies in species, genus and disease prevalence, assessing local risk (Yadav et al., 2019). Herd immunity, which is important for the control of infectious diseases, is tracked through vaccination in human and animal populations (Fine et al., 2011). Achieving herd immunity helps protect vulnerable individuals and reduce overall disease incidence, contributing to public health and economic stability.

Despite the benefits of vaccination, challenges remain in both human and veterinary contexts. These include addressing viral infections, particularly vaccine reluctance due to socio-cultural and economic influences, and structural barriers to vaccine availability in remote populations (Azzopardi, et al., 2009; Dubé et al., 2013). The development and use of species-specific vaccines is critical to protecting animals and populations from infectious diseases. Through scientific advances, regulatory controls, and strategies through the implementation of collective initiatives such as the Single Health System, we can effectively address the challenges posed by infectious diseases and enhance global health security.

**Challenges in Human and Veterinary Vaccinology**

Zoonotic illnesses pose a tremendous challenge in vaccinology. The transmission of pathogens like the rabies virus or avian influenza from animals to humans requires incorporated vaccination strategies. The improvement and distribution of vaccines must consider potential flora and fauna reservoirs, farm animal’s management practices, and the interface between wild and domestic animals (Karesh et al., 2012). Vaccine hesitancy, prompted by socio-cultural, political, and personal beliefs, is a major barrier to reaching vast immunity (Dubé et al., 2013). In veterinary medicinal drug, elements which includes the perceived risk-gain ratio and economic issues can affect compliance (Knight-Jones et al., 2014). Remote human populations often face demanding situations in having access to vaccination due to logistical, infrastructural, and useful resource obstacles (Wiysonge et al., 2013). Similarly, in veterinary medication, delivering vaccines too far off cattle or flora and fauna populations poses substantial logistical hurdles (Emily et al., 2022).

**Advances in Vaccine Technologies**

**Introduction to Adjuvants and Delivery Methods**

Adjuvants in veterinary science are important components added to vaccines to enhance the immune response of an animal to a given antigen. These factors play an important role in ensuring that the immune system recognizes and responds to the vaccine effectively (Wilson-Welder et al., 2009). Adjuvants work by promoting inflammation at the site of vaccine injection, attracting immune cells to the site, and improving antigen presentation to these immune cells (Reed et al., 2013). This results in a normal immune response strong, specific, prolonged against target infection or disease.

**Significance of Adjuvants in Veterinary Vaccines**

Immunogenicity: The primary role of adjuvants in veterinary vaccines is to activate the immune system. Many diseases have antigens that do not provoke a strong enough immune response on their own. Adjuvants help overcome these limitations by enhancing the immune response to the vaccine, thereby providing better protection against the disease (Wilson-Welder et al., 2009).

Increases long-term immunity: Promotes long-lasting immunity. They help produce memory cells, which "remember" the infection and can trigger a rapid and effective immune response should the animal become infected again in the future This is especially important for high-risk diseases worm of reinfection (cited by Reed et al., 2013).

**Types of Adjuvants Commonly Used in Veterinary Vaccines**

Aluminium salts (Alum): Chemical excipients containing aluminium such as aluminium hydroxide and aluminium phosphate are among the most common ingredients used in veterinary vaccines, they work by forming reservoirs in situ drops it, slows the release of antigen and increases the amount of antibody contact This long-term exposure increases the immune response (Wilson-Welder et al., 2009).

Oil-based excipients: Oil-based excipients, also known as emulsions, are water-based solutions of oil or oil. These adjuvants increase antigen retention at the injection site, resulting in prolonged immune activation. Examples include Freund's helper and Montanide (Reed et al., 2013).

New adjuvants: In recent years, researchers have developed adjuvants with specific ingredients. For example, CpG oligodeoxynucleotides activate the innate immune system by interacting with Toll-like receptors. Put simply, the immune system is more robust in this manner (Reed et al., 2013).

**Mechanisms of Action of Adjuvants**

Adjuvants promote inflammation because they stimulate prudent inflammation at the site of the eyes. As an explanation for that phenomenon, Wilson-Welder et al. (2009) state that under inflammatory conditions immune cells, specifically dendritic cells and macrophages, come to that locality creating an antigen tile environment. Dendritic cells and other antigen-presenting cells get this antigen by intake and processing and then delivering it more efficiently due to the increased antigen presentation. The immune system is therefore more efficient at comprehending the antigens as a threat and mounting a strong immune response after the ADC system has enhanced its antigen delivering capabilities (Reed et al., 2013).

Immune activation: Adjuvants can stimulate immune cells to serve as a source, and can increase the release of cytokines and chemokine’s, thus augmenting the level of immunological activity. Hence, through this, immune cells will reach the area more, thus, the immune response is coordinated well (Wilson-Welder et al., 2009).

A feasible way of looking at this is that adjuvants are a real part of any veterinary vaccine. They contribute to enhancement of the immune system caused by inflammation and as a result the release of immune cells and stimulant of the antigen thus. The adjuvants in veterinary vaccines may have different mechanisms of action; the selected adjuvant depends on parameters of the pathogen, the species, and the desirable time for which the response the immune system will last.

**Reverse Vaccinology**

This approach stands out in the rapidly evolving genomics technology landscape by utilizing digitalized information on the viral world to analyse genetic material and identify potential vaccine candidates, rather than relying on traditional methods of virus cultivation and study.

**Diseases**

Vaccines for bovine infections caused by multicide Teams of immunologists are now primarily responsible for developing methods to study Pasteurella's and Hemlitica's viruses. In genomics, scientists have precisely identified the surface proteins on ants and antigens crucial for vaccine development. Antigens are utilized in the creation of vaccines to protect animals from viral infections. *Streptococcus equi* subsp. *equi* is a significant infectious agent that poses a threat to horses. Research on a new vaccine for the disease has primarily utilized reverse vaccinology (Rappuoli et al., 2015). Virulence factors and surface proteins targeted by the immune system have been identified through viral genome analysis. Horses acquired and conscripted during the war played a significant role in advancing horse vaccines for infection and tetanus.

**How Genomic Analysis Led to Their Discovery**

Identifying specific regions on pathogen proteins or antigens that could initiate an immune response is a crucial step in genomics analysis. These antigens primarily contribute to virulence and are crucial for eliciting the host immune response. Vaccines could be developed based on gene candidates identified through genetic research. Research on vaccines entails introducing test antigens into the immune system of animals capable of producing protective immunity to develop the vaccine. As a result of these vaccinations, certain antigens are introduced to us through biotechnology and vaccinology. Producing the reporting chemical can be achieved through sub-unit vaccines, recombinant proteins, or other existing proteins, depending on the pathogen and the specific immune response required. Simply put, it resides on the surface of bacteria as if it were a bacterium but does not actively infect them. This is the rationale behind the statement (Rappuoli et al., 2015). Participants were instructed to review a persuasive argument advocating for the health advantages of protein-rich foods and offer their assessment of its persuasiveness. Enhancing immunity through adaptive vaccinology involves targeting a region closely aligned with the pathogen's genetic information, resulting in more effective and safer immunity. In addition, this method will render incoming vaccine batches ineffective as they would not target zoonotic diseases.

Animal research has proven to be a valuable method for testing various categories, such as reverse vaccinology, which involves the development of vaccines driven by immune genes (Rappuoli et al., 2015). Vaccinating cattle against respiratory disease and treating horses with crusted disease have significantly contributed to enhancing animal welfare. Identifying the essential proteins or genes that constitute specific vaccines is currently conducted through genomics-based methods. Despite its ancient origins, animal vaccination remains a crucial aspect of medicine.

**mRNA-Based Vaccine Models**

Their ability to achieve this in human beings forms the basis for a promising future regarding how mRNA-based vaccines might be of importance in veterinary medicine (Zhang et al., 2021). These influence host cells' antigens by changing the genetic code that is fixed in messenger RNA (mRNA) strands. Thereby, these offer immunogenicity and hence help high specificity because they make antibodies against the target pathogen.

**Vaccines for Animals Based on Messenger RNA**

mRNA-based vaccines are developing as potential game-changers and excellent armoury against a certain class of viral infections such as feline Leukaemia (Zhang et al., 2021). One of the examples: it may be designed to encode antigenic determinants of the feline Leukaemia virus and mimic a natural pathogen that will not cause disease. This stimulates the animal's immune system to produce a strong and specific anti-FeLV antibody that protects against the virus.

Prevention of viral diseases in animals (e.g., porcine reproductive respiratory syndrome - PRRS): mRNA-based vaccines hold promise for livestock, especially in the prevention of PRRS and other viral diseases in mice (Zhang et al., 2021). PRRS and mRNA vaccines can be designed to encode the major antigens of the PRRS virus. When fed to mice, the mRNA is translated into viral antigens in mouse cells. The administration of this preparation with a series of injections incites an immune response to the development of anti-PRRS antibodies. mRNA vaccines are developing very quickly but on high standards that are necessary to be coped with in combating new pathogens in animals.

**mRNA-Based Immunotherapy Procedures**

mRNA Delivery: This vaccine is usually administered by intramuscular injection. Messenger RNA (mRNA) is inoculated in the musculature; the host cell migrates and locates itself to a certain niche position near the area where it was injected. The vaccine serves as a blueprint to produce synthetic mRNA that carries antigenic information from the target pathogen.

Processing and translation of target antigen: The host machinery processes the mRNA and translates it into target antigens for presentation on the surface of infected host cells. Normally, these antigens could be viral proteins like capsids, or spike proteins in the case of viral infections.

The ones that are newly synthesized appearing on the surface of the host cell show that immune response is kick-started; more simply put, they function as flags that an invasion has taken place. In reaction, the immune system goes into overdrive, making antibodies and training T cells to destroy them.

Memory of Cells: Vaccinations based on messenger RNA also influence Memory of Cells. Immunity is maintained over time because these cells "remember" antigens. An animal's immune system may swiftly develop targeted defences in the event of future infection.

**Benefits of Veterinary Vaccines Derived from mRNA**

A particular disease may be swiftly and effectively targeted using mRNA vaccines. For the sake of veterinary disease prevention, these alterations are crucial (Zhang et al., 2021). With mRNA vaccines, antigens may be selected with great precision, directing the immune response to target specific portions of the pathogen. There is less chance of infection with mRNA vaccinations since they do not employ live viruses. When applied to animals, they do not pose any health risks. Veterinary applications and companion animals: mRNA-based vaccinations may be used to protect farm animals (such as pigs and cattle) and companion animals (such as cats and dogs) against a variety of viral infections.

Rapid development, accurate antigen selection, and increased safety are three ways in which mRNA-based vaccines might change veterinary medicine forever. It offers an efficient method of reducing infectious disease outbreaks in livestock populations and may be used to reduce viral illnesses in both companion animals and cattle. With the ongoing research in this field, mRNA-based vaccinations are expected to take centre stage in the fight against and control animal illnesses.

**Animal Models in Vaccine Development**

Vaccine research and development greatly benefit from the use of animal models of human immunity. In most cases, the immune systems of the animals are altered genetically to resemble that of a human being. It is mainly used to test possible vaccine candidates before heading to clinical trials in animals targeted for vaccination. Preclinical animal testing modelling human immune responses may help predict safety and efficiency for animals such as pets, cattle, and the wild (Melkus et al., 2006).

An animal model of human immunity allows a more scientific analysis of diseases but under regulated conditions; this makes them obtain information regarding the disease processes and pathogen interaction as well as immune responses which are the basic components that will help in guiding the design of effective vaccines. Animal models rank as the most important component for assessing a number of possible candidates for vaccination. These are subjected to a rigorous testing process to ascertain safety and effectiveness before vaccination is carried out amongst animal populations. An animal model is one important way of checking the efficacy of the vaccine candidate on protection and induction of the appropriate immune response against the target infection. On the other hand, animals use these models to decide whether a given potential vaccine may be safe or not. It is a part of general vaccination safety, potential side effects, and adverse event screening (Shultz et al., 2007).

**Applications of Animal Models in Veterinary Vaccine Development**

These vaccines are therefore screened on companion animals, among them horses, cats, and dogs. For example, vaccines can be used in assessing the success of canine parvovirus vaccinations in prevention and guarding against the virus.

The agriculture sector majorly relies on livestock. For instance, some vaccinations can be tested with their use as models of pigs, chickens, and cattle. A model used in the testing of economically significant illnesses such as foot and mouth and respiratory disease in pigs, it might be the model itself (Dwivedi et al., 2012; Zhang et al., 2013). Use animal models to benefit wildlife conservation efforts. Vaccines that have been developed for populations of endangered animals or for infectious diseases to which certain animals are particularly susceptible, like distemper, may also be tested on experimental animals for safety (Daszak et al., 2000, Wolcott et al., 2000).

**What a Humanized Immune System Animal Models Operate**

Animal models of human immunity are developed using genetic alteration. It is an attempt at mimicking the effectiveness of an immune system through the insertion, deletion, or mutation of some genes that are related to these immunities. Mice can be developed to yield those antibodies and their components which are normal products in human beings. Sometimes animals are adapted as a model of humans after having implanted in them human tissues or cells. To imitate the immunological reaction of people, humanized mice are administered human bone marrow or thymus tissue (Rongvaux et al., 2014). After the construction, these animal models are immunized with the respective vaccine and then deliberately faced by the target pathogen to prove the efficiency of the vaccine. Terms of resistance or immunity to the disease, immunogenicity measures, as well as security, are also evaluated.

Most of the vaccines developed for animals have been developed along with or based on animal models of human immunity. Most likely, they may first research animal diseases to determine potential candidates for vaccines among domestic animals, cattle, and wildlife, besides finding out its safety and efficiency before introducing a vaccine for specific populations. By adoption of this model in the protection and knowledge of animal health, it will be possible to do this job in a very perfect way.

**CRISPR Technology in Vaccine Design**

Application of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system is highly promising in precise genetic modification, appearing now also as an effective tool in the preparation of animal vaccines. Thus, enhancement of the immunogenicity of antigens or preparing more effective or less dangerous vaccines based on live attenuated strains of viruses becomes feasible with the help of CRISPR. Using CRISPR, antigens in a vaccine can have their genetic composition remodelled in ways that greatly enhance the potency of stimulating a much stronger and much more targeted immune response. This could include upregulating levels of epitope presentation or even altering programming for improved antigen-antibody recognition or even designing specific epitopes which enhance responses to Abs. Further, weakened vaccines can be delivered that are equipped to elicit disease responses. Where safety concerns are paramount, the use of the method becomes valuable if after where safety concerns are paramount, CRISPR could contribute to drug development and therapeutics if it is used to improve antigen presentation to effectively vaccinate against specific viral diseases in veterinary. Researchers can rapidly target vaccines to respond to potentially harmful new viruses, which is especially important for viral diseases affecting animals and humans Although CRISPR offers precision in genetic analysis in 2010, safety assessment, ethical considerations, and regulatory oversight are essential elements to ensure the safety and efficacy of these new vaccines.

**One Health and Global Immunization Efforts**

The one health approach recognizes the interplay between human, animal, and environmental health, with an emphasis on communicating strategies for the prevention and control of diseases affecting humans and animals. This approach recognizes that diseases in different populations and the need for concerted efforts to effectively prevent disease, Ebola and many others Infectious diseases are animal vectors of disease, emphasizing the importance of human and animal emphasize health togetherness. One Health emphasizes early detection and surveillance of diseases at the human-animal-environment interface, monitoring human and animal diseases to identify potential outbreaks and prevent their spread. Vaccination is recognized as a key component of preventing viral diseases in One's Health strategies, including to reduce and protect public health, vaccination programs targeting human and animal populations have been developed (Mackenzie et al., 2013).

**Case Studies of Successful One Health Vaccination Campaigns**

Successful One Health vaccination campaigns have been critical in the prevention of various viral diseases. For example, in areas where rabies is endemic, One Health vaccination campaigns target dogs and humans to significantly reduce human rabies cases through herd immunity in dogs and responsible pet ownership promoting use as well as monitoring, and early detection through One Health vaccination campaigns in poultry farms to prevent avian influenza outbreaks, reducing the risk of human infection and health about vaccinating personnel during One Health's procedures for Ebola virus outbreaks, human and animal populations monitored to prevent the spread of the virus These are examples of One Health vaccination campaigns publication of coordinated veterinary disease prevention and human animal protection health efforts (World Health Organization, 2020).

**Future Directions**

**Predictive Vaccinology and Disease Eradication Goals**

**Predictive Vaccinology**

Predictive vaccinology is a revolutionary approach to vaccine development that uses advances in genomics, computational biology, and immunology to predict and develop vaccines with incredible accuracy. This approach has made a difference in vaccine design and greatly accelerated vaccine development. Here’s a look at how predictive vaccine science is changing the landscape of vaccine development:

**Leveraging Genomics**

Whole viral genomes are now open for new avenues of prediction with the vaccination candidates in hand. Important antigen determinants would allow the narrowing down of genomic data elements from the virus that are most worthy of being used in vaccines.

**Biological Computation**

This process will have much to do with computational methods and the application of technology in the forecasting of probable vaccines. Bioinformatics is used for the better understanding of the immune system, for examinations of the bacterial genome, and findings of possible antigenic epitopes, thus avoiding many experimental needs at the vaccine development time.

**Customizing Immunizations**

Individuals’ unique vaccination requirements may be satisfied with the help of predictive vaccinology. To maximize the effectiveness of vaccinations, it is necessary to comprehend the genetic diversity among the host population.

**Progress Acceleration**

The time it takes to produce vaccinations is reduced via predictive vaccinology. Researchers may speed up the implementation of vaccinations by accelerating preclinical and clinical studies once they swiftly identify the most promising candidates.

**Disease Eradication Goals**

On the forefront of global health agendas have been ambitious targets for disease prevention. These objectives seek to eradicate certain diseases by implementing extensive immunization programs. Key elements of preventative aims include the following:

**Campaigns to Get Rid of Polio**

The Global Polio Eradication Initiative is one of the best examples of an attempt to stop diseases before they happen. The initiative has made significant strides in reducing polio worldwide through widespread vaccination campaigns. But challenges remain, including reaching vulnerable and conflict-affected populations.

**Eliminating Guinea Worm Disease**

Guinea worm disease caused by *Dracunculus medinensis* is on the verge of extinction. Extensive efforts to provide safe water supply, monitoring and prevention have led to a dramatic reduction in incidents.

**Measles Elimination**

Goals of gonorrhoea prevention goals are to reduce the incidence of gonorrhoea disease to a point where it no longer circulates within a region. Vaccination campaigns, routine vaccination and surveillance are important components of smallpox prevention strategies.

**Interdisciplinary Collaboration Opportunities**

**Cross-Species Collaboration**

Since diseases have a human-animal relationship, cooperation in human-veterinary vaccination is essential. The main features of interracial harmony are:

**Zoonotic Diseases**

Many diseases, including avian influenza, Ebola, and smallpox, can be transmitted between animals and humans. Collaboration can also lead to shared strategies and research for the prevention and control of viral diseases.

**Shared Knowledge**

The exchange of knowledge and insights between humans and veterinarians with vaccines can lead to more effective vaccines and better disease prevention strategies.

Include examples of how people have worked together successfully to stop viral diseases, like the "One Health" approach to the flu virus or the group effort to fight new pandemics.

**Global Health Partnerships**

To overcome obstacles to immunization and reach global safety objectives, global health collaborations are essential. These relationships mostly consist of:

**Various Global Groups**

Assuring access to vaccinations and supporting research, organizations like WHO, UNICEF, and the GAVI Alliance play a crucial role in global immunization efforts.

**Public-Sector Partnership**

Immunization programs, border disease monitoring, and vaccine delivery all rely on intergovernmental collaboration.

**Not-for-profit organizations and research centres**

Global health relationships benefit from the information, funding, and new ideas that NGOs and study groups bring to the table.

**Research on New Diseases**

To study and deal with new viral diseases, people must work together, and foreign teamwork is very important.

**Interdisciplinary Research Teams**

To solve complicated health problems and enhance vaccination technology, multidisciplinary research teams consisting of specialists in immunology, genetics, epidemiology, animal science, and public health are necessary.

**Extensive Knowledge**

Emerging diseases that are transmissible, vaccinations, and other complex health concerns are the focus of these organizations' combined knowledge and experience.

**Innovation**

Interdisciplinary collaboration supports the development of new products and approaches in vaccine research, such as predictive vaccinology.

**Addressing Complex Challenges**

Teams are set to tackle the complex challenges at the intersection of human and animal health, including viral diseases and One Health programs.

## REFERENCES


Abidin, A., and Budi, A. (2021). Rabies Preventions In Humans In The Working Area Of East Tomoni Public Health Center. Nurse and Health: *Jurnal Keperawatan*, 10(2), 249-256.

Acharya, K. P., Karki, S., Shrestha, K., and Kaphle, K. (2019). One health approach in Nepal: Scope, opportunities and challenges. *One Health*, 8, 100101.

Artaud, C., Kara, L., and Launay, O. (2019). Vaccine development: from preclinical studies to phase 1/2 clinical trials. Malaria Control and Elimination, pp (165-176).

Azzopardi, P., Bennett, C. M., Graham, S. M., and Duke, T. (2009). Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review. *The International Journal of Tuberculosis and Lung Disease*, 13(11), 1331-1344.

Behbehani, A. M. (1983). The smallpox story: life and death of an old disease. Microbiological reviews, 47(4), 455-509.

Brunette Gary, W. N. J. B., and Nemhauser Jeffrey, B. (2020). CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2019..

Centers for Disease Control and Prevention. (2020). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2020. National Center for Immunization and Respiratory Diseases. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. October 15, 2021.

Cole, A., Webster, P., Van Liew, D., Salas, M., Aimer, O., and Malikova, M. A. (2022). Safety surveillance and challenges in accelerated COVID-19 vaccine development. *Therapeutic Advances in Drug Safety*, 13, 20420986221116452.

Corum, J., and Zimmer, C. (2020). How Moderna's Vaccine Works. Retrieved from The New York Times: 12, 2021, from https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html

Daszak, P., Cunningham, A. A., and Hyatt, A. D. (2000). Emerging infectious diseases of wildlife--threats to biodiversity and human health. *Science*, 287(5452), 443-449.

Decaro, N., Desario, C., Billi, M., Mari, V., Elia, G., Cavalli, A., Martella, V., and Buonavoglia, C. (2011). Western European epidemiological survey for parvovirus and coronavirus infections in dogs. *The Veterinary Journal*, 187(2), 195-199.

Department of Health Services. Vol. 75. 2019. Annual report 2075/75 (2017/18) pp. 1–476.https://dohs.gov.np/annual-report-2074-75

Devleesschauwer, B., Aryal, A., Sharma, B. K., Ale, A., Declercq, A., Depraz, S., Gaire, T. N., Gongal, G., Karki, S., Pandey, B. D., Pun, S. B., Duchateau, L., Dorny, P., and Speybroeck N. (2016) Epidemiology, impact and control of rabies in Nepal: a systematic review. *PLOS Neglected Tropical Diseases*, 10(2), e0004461.

Dodds, W. J. (2021). Early Life Vaccination of Companion Animal Pets. Vaccines, 9(2), 92.

Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., and Bettinger, J. A. (2013). Vaccine hesitancy: an overview. *Human Vaccines and Immunotherapeutics*, 9(8), 1763-1773.

Dwivedi, V., Manickam, C., Binjawadagi, B., Linhares, D., Murtaugh, M. P., and Renukaradhya, G. J. (2012). Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. *Virology Journal*, 9(1), 1-9.

Ellis, W. A. (2015). Animal leptospirosis. Leptospira and leptospirosis, 99-137.

Emily, A. B., Barekye, B., Bower, H., Mazuguni, F., Maruta, T., Loembé PhD, M. M. M., Numbere, T. W., Muita, M., Maeda, J., Mankoula, W., and Nkengasong, J. N. (2022). Population-Based Serosurveys for SARS-CoV-2: Key Findings From Five African Countries: November 2020 to June 2021. Available at SSRN 4040702.

Erkyihun, G. A., and Alemayehu, M. B. (2022). One Health approach for the control of zoonotic diseases. *Zoonoses*, 2, 37.

Fenner, F., Henderson, D. A., Arita, I., Ježek, Z., and Ladnyi, I. D. (1988). Smallpox and its eradicationcontinued. Geneva: World Health Organization.

Fine, P., Eames, K., and Heymann, D. L. (2011). "Herd immunity": a rough guide. Clinical infectious diseases, 52(7), 911-916.

Geison, G. L. (1996). The private science of Louis Pasteur. Princeton University Press.

Janeway, C., Travers, P., Walport, M., and Shlomchik, M. J. (2001). Immunobiology: the immune system in health and disease (Vol. 2, p. 154). New York: Garland Pub.

Karesh, W. B., Dobson, A., Lloyd-Smith, J. O., Lubroth, J., Dixon, M. A., Bennett, M., Aldrich, S., Harrington, T., Formenty, P., Loh, E. H., and Machalaba, C. C., (2012). Ecology of zoonoses: natural and unnatural histories. The Lancet, 380(9857), 1936-1945.

Knight-Jones, T. J. D., Edmond, K., Gubbins, S., and Paton, D. J. (2014). Veterinary and human vaccine evaluation methods. *Proceedings of the Royal Society B: Biological Sciences*, 281(1784), 20132839.

Kumari, M., Lu, R. M., Li, M. C., Huang, J. L., Hsu, F. F., Ko, S. H., Ke, F. Y., Su, S. C., Liang, K. H., Yuan, J. P. Y. and Chiang, H. L.

(2022). A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. *Journal of Biomedical Science*, 29(1), 68.

Kutzler, M. A., and Weiner, D. B. (2008). DNA vaccines: ready for prime time?. *Nature Reviews Genetics*, 9(10), 776-788.

Mackenzie, J. S., Jeggo, M., Daszak, P., and Richt, J. A. (2013). One Health: The human-animal-environment interfaces in emerging infectious diseases (Vol. 366). Berlin: Springer.

Mealey, R. H. (2014). New Perspectives in Infectious Diseases, An Issue of Veterinary Clinics of North America: Equine Practice (Vol. 30, No. 3). Elsevier Health Sciences.

Melkus, M. W., Estes, J. D., Padgett-Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., Wege, A. K., Haase, A. T. and Garcia, J. V. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nature medicine, 12(11), 1316-1322.

Murphy, K., and Weaver, C. (2016). Janeway's immunobiology. Garland science.

Offit, P. A. (2005). The Cutter incident, 50 years later. *New England Journal of Medicine*, 352(14), 1411-1412.

Orenstein, W., Offit, P. A., Edwards, K. M., and Plotkin, S. A. (2017). Vaccines E-Book. Elsevier Health Sciences.

Pardi, N., Hogan, M. J., Porter, F. W., and Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. *Nature Reviews Drug Discovery*, 17(4), 261-279.

Pasteur, L., and Halsall, P. (1998). Extension of the Germ Theory.

Petkar, K. C., Patil, S. M., Chavhan, S. S., Kaneko, K., Sawant, K. K., Kunda, N. K., and Saleem, I. Y. (2021) An overview of nanocarrier-based adjuvants for vaccine delivery. *Pharmaceutics*, 13(4), 455.

Plotkin, S. A., Orenstein, W., and Offit, P. A. (2012). Vaccines E-book. Elsevier Health Sciences.

Pollard, A.J., and Bijker, E. M. (2021). A guide to vaccinology: From basic principles to new developments. *Nature Reviews Immunology*, 21(2):83-100.

Rappuoli, R., Bottomley, M. J., D'Oro, U., Finco, O., and De Gregorio, E. (2016). Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. *Journal of Experimental Medicine*, 213(4), 469-481.

Ratcliffe, M. J., and Härtle, S. (2022). B cells, the bursa of Fabricius, and the generation of antibody repertoires. In Avian immunology (pp. 71-99). Academic Press.

Reed, S. G., Orr, M. T., and Fox, C. B. (2013). Key roles of adjuvants in modern vaccines. Nature medicine, 19(12), 1597-1608.

Riedel, S. (2005, January). Edward Jenner and the history of smallpox and vaccination. In Baylor University medical center proceedings (Vol. 18, No. 1, pp. 21-25). Taylor and Francis.

Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., and Flavell, R. A. (2014). Development and function of human innate immune cells in a humanized mouse model. *Nature Biotechnology*, 32(4), 364-372.

Roura, X., Cortadellas Rodríguez, Ó., Day, M. J., Benali, S. L., and Zatelli, A. (2021). Canine leishmaniosis and kidney disease: QandA for an overall management in clinical practice. *Journal of Small Animal Practice*, 62, E1-E19.

Schiller, J. T., and Lowy, D. R. (1996). Papillomavirus-like particles and HPV vaccine development. In Seminars in cancer biology (Vol. 7, No. 6, pp. 373-382). Academic Press.

Shaffer, H. B., Fellers, G. M., Magee, A., and Voss, S. R. (2000). The genetics of amphibian declines: population substructure and molecular differentiation in the Yosemite toad, Bufo canorus (Anura Bufonidae) based on single-strand conformation polymorphism analysis (SSCP) and mitochondrial DNA sequence data. *Molecular Ecology*, 9(3), 245-257.

Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., and Greiner, D. L. (2012). Humanized mice for immune system investigation: progress, promise and challenges. *Nature Reviews Immunology*, 12(11), 786-798.

Shultz, L. D., Ishikawa, F., and Greiner, D. L. (2007). Humanized mice in translational biomedical research. *Nature Reviews Immunology,* 7(2), 118-130.

Spibey, N., Greenwood, N. M., Sutton, D., Chalmers, W. S. K., and Tarpey, I. (2008). Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. *Veterinary Microbiology*, 128(1-2), 48-55.

Uribe, C., Folch, H., Enríquez, R., and Moran, G. J. V. M. (2011). Innate and adaptive immunity in teleost fish: a review. *Veterinarni Medicina*, 56(10), 486-503.

Wakhusama, S. W., Bastiaensen, P., Bouguedour, R., Letshwenyo, M., Tounkara, K., Mérot, J., Ripani, A., Gregorio, T., Renaudin, S., Bertrand-Ferrandis, C., and Erlacher-Vindel, E. (2019). The World Organization for Animal Health (OIE)'s engagement towards Rabies Elimination in Africa. *Journal of Veterinary Medicine and One Health*, 1(1), 3-14.

Wang, S., Li, L., Yan, F., Gao, Y., Yang, S., and Xia, X. (2021). COVID-19 animal models and vaccines: current landscape and future prospects. *Vaccines*, 9(10), 1082.

Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., and Narasimhan, B. (2009). Vaccine adjuvants: current challenges and future approaches. *Journal of Pharmaceutical Sciences*, 98(4), 1278-1316.

Wiysonge, C. S., Uthman, O. A., Ndumbe, P. M., and Hussey, G. D. (2013). A bibliometric analysis of childhood immunization research productivity in Africa since the onset of the Expanded Program on Immunization in 1974. *BMC Medicine*, 11(1), 1-10.

World Health Organization, (2020). One Health. Retrieved from https://www.who.int/news-room/q-a-detail/one-health

World Health Organization, (2020). The immunological basis for immunization series: module 7: measles: update 2020.

Yadav, M. P., Singh, R. K., and Malik, Y. S. (2019). Epidemiological perspective in managing viral diseases in animals. *Recent Advances in Animal Virology*, 381-407.

Zeng, C., Zhang, C., Walker, P. G., and Dong, Y. (2020) Formulation and Delivery Technologies for MRNA Vaccines. *Current*

*Topics in Microbiology and Immunology*, 2020, 6, 1–40.
Zhang, C., Maruggi, G., Shan, H., and Li, J. (2019). Advances in mRNA vaccines for infectious diseases. *Frontiers in Immunology*, 10, 594.
Zhang, L., Feng, X., Jin, Y., Ma, J., Cai, H., and Zhang, X. (2016). Immunoprotective mechanisms in swine within the "grey zone" in antibody response after immunization with foot-and-mouth disease vaccine. *Virus Research*, 220, 39-46.
Zhang, Y. A., Salinas, I., and Sunyer, J. O. (2011). Recent findings on the structure and function of teleost IgT. *Fish and Shellfish Immunology*, 31(5), 627-634.
Zhang, Y., Kang, J.Y., Liu, M., and Huang, Y. (2023). Diverse roles of biomolecular condensation in eukaryotic translational regulation. *RNA Biology*, 20 (1), 893-907